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ABSTRACT 
Background: Glucocorticoids are the gold standard treatment of bronchial asthma. Although the majority of patients 
with asthma respond favorably to inhaled and systemic steroid therapy, a subset of asthmatics failed to demonstrate 
a satisfactory response even to systemic glucocorticoid therapy. GCR β (glucocorticoid receptor beta) is a hormone 
binding deficit isoform of GCR (glucocorticoid receptor) which has been isolated in humans and when over 
expressed, it may function as a dominant negative modulator of GCR. Aim of the  work: This study was designed 
to determine the percentage of expression of GCRβ on PBMCs: (peripheral blood mononuclear cells )of asthmatic 
patients and to correlate it with the clinical severity and pulmonary functions. Subjects and Methods: 60 asthmatic 
patients (41 males, 19 females) and 20 healthy controls were enrolled in this study. Asthmatics were classified 
according to GINA guidelines (2002) into mild, moderate and severe asthma. They were subdivided into asthmatic 
on inhaled corticosteroid (ICS) (n=35) and those not on ICS (n=25). For all studied groups, spirometeric pulmonary 
functions and immunohisto-chemistry staining of PBMCS were performed to analyze percentage of expression of 
GCRβ on PBMCs. Results: It showed that the percentage of expression of GCRβ on PBMCS were statistically 
higher in all asthmatic patient groups compared to control, with higher % of expression in those not on ICS. Also a 
statistical significant higher % of expression of GCR β in severe asthmatics compared to both mild and moderate 
groups was detected. In conclusion: This study highlights the importance of glucocorticoid receptor beta isoform in 
pathogenesis of  bronchial asthma and this may be directly linked to asthma severity and can affect the response to 
medications especially ICS. [New York Science Journal 2010;3(5):54-62]. (ISSN: 1554-0200). 
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 Introduction
Glucocorticoids are the gold standard treatment of 
asthma affecting most of the components involved in 
bronchial inflammation as inflammatory cells and 
bronchial structure cells.21 Glucocorticoids modulate a 
large number of metabolic, cardiovascular, immune, and 
behavioral functions. The biological action of 
glucocorticoids is mediated through the activation of 
intracellular glucocorticoid receptors (GR). The GR 
belongs to the superfamily of steroid/thyroid/retinoid 
acid receptor proteins that function as ligand-dependent 
transcription factors. 12 
Inhaled and intranasal glucocorticoids are the most 
common and effective drugs for controlling symptoms 
and airway inflammation in respiratory diseases such as 
asthma, allergic rhinitis, and nasal polyposis.24 The last 
few years have seen a growing understanding of the 
mechanisms of glucocorticoid action and, in particular, 
the receptor that mediates glucocorticoid actions, the 
glucocorticoid receptor (GR). The human glucocorticoid 
receptor gene encodes two protein isoforms; GCRα 
which binds glucocorticoids, translocates to the nucleus 
and regulates gene transcription, GCRβ which does not 
bind GC and alters GCRα action  and may therefore 
interfere with action of glucocorticoid. Increased 
expression of GCR β in inflammatory cells might be a 
critical mechanism for conferring glucocorticoid 
resistance.8  
Understanding the mechanisms that control GC 
insensitivity will be important in developing alternative 
therapies for these patients whose disease tends to be 
severe  and in minimizing side effects from long-term 
systemic GC therapy, by allowing early identification of 
biomarkers that predict GC insensitivity.20 In this 
revision we present an update on the GR gene, the 
expression and regulation of its gene products, namely 
GRalpha and GRbeta, as well as their alterations in 
pathological states. GRalpha has a widespread 
distribution and is responsible for the induction and 
repression of target genes, and the one that shows 
steroid binding activity, it is expressed in virtually all 
human cells and tissues, and its expression is known to 
be downregulated by glucocorticoids, whereas GRβ can 
act as a dominant negative inhibitor of GRα-mediated 
transactivation and transrepression. 5 GRbeta has been 
found to act as a dominant negative inhibitor of 
GRalpha-mediated transactivation in vitro studies with 
transfected cells, but it does not appear to have a 
significant inhibitory effect on GRalpha-mediated 
transrepression. In addition, for most tissues the 
expression of GRbeta, at least at the mRNA level, is 
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extremely low compared with that of GRalpha. 12 Some 
pro-inflammatory cytokines appear to upregulate the 
expression of GRbeta, and increased GRbeta 
Glucocorticoid (GC) insensitivity is a challenging 
clinical problem associated with life-threatening disease 
progression. Glucocorticoid-resistant asthma is 
associated with enhanced mononuclear cell–mediated 
airway inflammation, which is unresponsive to the anti-
inflammatory effects of glucocorticoids. 21 
Pro-inflammatory cytokines appear to upregulate the 
expression of GRbeta, and increased GR beta  
expression has been reported in diseases associated with 
glucocorticoid resistance or insensitivity, such as 
bronchial asthma, nasal polyposis, and ulcerative colitis. 
However, the possible role of GRbeta in modulating 
glucocorticoid sensitivity and/or resistance in vivo has 
been highly debated and it is not yet clear. 6 
Although the majority of patients with asthma respond 
favorably to inhaled and systemic steroid therapy, a 
subset of asthmatics failed to demonstrate a satisfactory 
response even to systemic glucocorticoid therapy. 20) It 
is important to recognize those patients early because 
failure to respond to steroids leads to prolonged courses 
of high dose of glucocorticoid therapy and serious 
adverse effects despite persistent airway compromise.23    
Glucocorticoid-resistant bronchial asthma is 
characterized by failure of corticosteroids to supresss 
key asthma-relevant, cell-mediate inflammatory 
responses in the airways. Although this phenomenon is 
relatively uncommon, it poses a difficult therapeutic 
problem because few alternative therapies are 
available.12 
Glucocorticoid-sensitive asthma was defined as an 
increase in FEV1 of at least 30% after a 2-week course 
of oral prednisolone 40 mg daily, corrected for body 
surface area. Glucocorticoid-resistant asthma was 
defined as a less than 15% improvement in FEV1 after a 
similar course of corticosteroids. 6 
 
Aim of the  work: This study was carried to determine 
the role of glucocorticoid receptor beta (GCRβ) in 
asthmatic patients through assessment of its percentage 
of expression on peripheral blood mononuclear cells 
(PBMCs) and its relation to the clinical severity of the 
disease, their pulmonary functions and their response to 
steroid therapy. 
 
Subjects  and methods: 60 asthmatic patients were 
enrolled in this study . They were selected from patients 
attending the chest and internal medicine clinics, Ain 
Shams University for follow up and treatment. 
All participants were subjected to: 
A- Full history taking and thorough clinical 
examination, especially stressing on episodic wheezing 
(has the patient had an attack or recurrent attacks of 
wheezing?), does the patient have a troublesome cough 
at night? does the patient wheeze or cough after 
exercise?, does the patient experience wheez, chest 
tightness, or cough after exposure to airborne allergens 
or pollutants?, do the patient's colds go to the chest” or 
take more than 10 days to clear up?, are symptoms 
improved by appropriate asthma treatment? 
B- Chest x-ray: To exclude other pulmonary diseases. 
C- Spirometric pulmonary function tests:  Spirometric 
pulmonary function tests (FVC, FEV1, and FEV1/FVC) 
were measured using spirometer. Simple spirometry is 
the recommended method of measuring airflow 
limitation and reversibility to establish a diagnosis of 
asthma. Measurements of FEV1 and FVC are 
undertaken during a forced expiratory maneuver using a 
spirometer. Recommendations for the standardization of 
spirometry have been published. 26 
Spirometry is effort-dependent. Therefore, proper 
instructions on how to perform the forced expiratory 
maneuver must be given to patients, and the highest 
value of three recordings taken. As ethnic differences in 
spirometric values have been demonstrated, appropriate 
predictive equations for FEV1 and FVC should be 
established for each patient.  Because many lung 
diseases may result in reduced FEV1, a useful 
assessment of airflow limitation is the ratio of FEV1 to 
FVC. The FEV1/FVC ratio is normally greater than 
0.75 to 0.8.  Any values less than these suggest airflow 
limitation. 
The data obtained from this maneuver were: 
* FVC      : Forced vital capacity (L). 
* FEV1   : Forced expiratory volume in first second (L). 
* FEV1/FVC:  percentage of expired volume in first 
second (FEV1%) divided by forced vital capacity. 
* PEFR:   Peak expiratory flow rate (L/S).  
These parameters were expressed as percentage of 
predicted values. The predictive values for each subject 
based on sex, age and height were obtained from 
standard tables. Abnormal values were considered to be 
< 80% for each of them of the predicted values. 26 
Patients with a diagnosis of asthma, were based on The 
American Thoracic Society criteria were selected for 
evaluation. They were included if they had  12% 
increase (reversibility) in forced expiratory volume in 
one second (FEV1)  (or ≥ 200 ml) after two inhalations 
of 400 g salbutamol (i.e, from the pre-bronchodilator 
value).13   
They were classified according to asthma severity based 
upon GINA guidelines 2006 into: 
1-Mild persistent asthma: 20 patients they were 15 
males and 5 females. 
2- Moderate persistent asthma: 20 patients, they were  
13 males and 7 females. 
3-Severe asthma: 20 patients, they were 12 males and 8 
females. 
 Patients were subdivided according to the intake of 
inhaled steroids into:  
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35 asthmatics on inhaled steroids (25 males and 10 
females) with a mean age 31±3.05 years. 
25 asthmatics not on inhaled steroids (16 males, 9 
females) with a mean age of 30.35±2.26 years. 
Age and sex matched 20 healthy individuals were 
chosen as control group to be included in the study. 
 Patients were excluded if they had evidence for other 
types of lung diseases, and asthmatic patients who were 
given systemic steroids within the last 8 weeks.  
 D- Complete blood picture laying stress on total 
leucocytes count and absolute eosinophilic count. 
E- Estimation of GCRβ in PBMCs by immuno-
histochemistry: Venous blood samples were drawn from 
each patient, mono-nuclear cells (mnc) were carefully 
collected from phosphate buffer solution (PBS) / Ficoll-
Hypaque interface with a Pasteur pipette and transferred 
to a new tube. Immuno-cyto-chemical staining by 
Polyclonal antibody (SC-1003) and Histo-stain SP 
universal kit used for staining of cell smears. 13 
Statistical analysis: 
After collection of data, each was coded and entered 
into a personal computer statistical analysis was done 
using SPSS program version 8 (Statistical Package for 
Social Science). 
The following Statistical tests were used: Mean (X) and 
standard deviation (SD) to describe quantitative data. 
e.g age .Simple frequency tables include number (N) 
and percent (%) to describe qualitative data. e.g. sex. 
Chi-Square test (X2) to compare two independent 
groups in qualitative variables. Student “t” test was used 
to compare mean of two groups .ANOVA (Analysis Of 
Variance) (F value) was used to compare mean of more 
than two groups. Pearson correlation (r) to correlate two 
variables in the same group. P>0.05 was considered 
insignificant, p < 0.05 was considered significant. p < 
0.01 was considered highly significant . 
 
RESULTS 
This study included 60 asthmatic patients and 20 
healthy individuals as a control group. The asthmatic 
patients were 41males and 19 females, their age ranged 
from 21 to 45 years with a mean age of 31.34±5.57 
years. The control group was age and sex matched. 
They   were 11 males, 9 females, their age ranged from 
20 to 44 years, with a mean age of 31.62±2.60 years. 
The asthmatic patients were classified according to 
asthma severity based upon GINA guidelines 2006 into: 
1-Mild persistent asthma: 20 patients (15 males and 5 
females) with a mean age of 31.54±5.54 years. 
2- Moderate persistent asthma: 20 patients (13 males 
and 7 females) with a mean age of 32.41±6.97 years. 
3-Severe asthma: 20 patients (12 males and 8 females) 
with a mean age of 30.91±1.57 years. 
Patients were subdivided according to the intake of 
inhaled steroids into:  
• 35 asthmatics on inhaled steroids (25 males, 10 
females) with a mean age 31±3.05 years. 
• 25 asthmatics not on inhaled steroids (16 males, 9 
females) with a mean age of 30.35±2.26 years. 
Comparing the clinical groups of asthmatic patients 
(mild, moderate, and severe asthma), this work showed 
that there was a statistical significant difference 
(P<0.05) between the three groups as regards the 
absolute eosinophilic count but there is no statistical 
significant difference (P>0.05) between them regarding 
TLC/m3 (table 2). Also it showed that there was a 
statistical highly significant difference (P<0.001) 
between the three groups as regards spirometric 
pulmonary functions tests with lower values in 
moderate and severe groups (table 2). 
Our study showed a statistically significant increase in 
percentage of expression of GCR β on PBMC's in 
asthmatic group (8.64±I4.35%) as compared to control 
group (2.05±0.99) (p<0.01) (table 1). 
Also it showed that there was a statistical significant 
difference (P<0.001) in % of expression of GCR β in 
severe group as compared to mild and moderate 
groups (table 3). 
This work showed that there was no statistical 
significant difference (P>0.05)  between asthmatics on 
ICS and asthmatics not on ICS as regards total 
leucocytes count and absolute eosinophilic count (table 
4). However the level of pulmonary function tests were 
significantly higher in asthmatics on ICS compared to 
asthmatics not on ICS (p<0.001) (table 4). 
The percentage of expression of GCR β on PBMCs was 
statistically higher in asthmatic pateints whether they 
are on ICS or not on ICS compared to control (p<0.001) 
with significantly higher  percentage of expression in 
asthmatics not on ICS compared to asthmatics on ICS. 
(p<0.001) (table 5 & fig.1). 
There was statistical significant negative correlation 
between GCR β expression and PEFR (table 6, fig.2). 
On the other hand, there were insignificant correlation 
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GCR β(% of 
expression) 2.05 ±0.99 8.64 ±14.35 <0.01 
 
Table (2): Comparison between asthmatic subgroups as regards clinical parameter, 
some, laboratory parameters and spirometric pulmonary functions tests 







<0.05 2.87 540 ±230 412 ±210 271± 138 Absolute eosinophils /m3 
<0.001 29.99 41.20±12.28 64.38 ±4.20 81.29 ± 7.69 FEV1 (% of predicted) 
<0.001 26.24 53.40  ±12.24 73.62±6.23 86.57±5.32 FVC(% of predicted) 
<0.05 3.21 36.80±14.72 62.50±25.93 72.29± 27.22 PEFR (% of predicted) 
 
Table (3): Statistical comparison between asthmatic subgroups as regards % of expression of GCR β on 
PBMCs. 





<0.001 17.10 15.80 ±4.44 12.11±1.81 8.28 ± 1.11 GCR β (% of expression) 
 
Table (4): comparison between asthmatics on ICS and asthmatics not on ICS as regards some laboratory 
parameters and spirometric pulmonary functions tests. 








eosinophilis/mm3 480 ±225 395 ±211 1.29 >0.05 
FEV1 
(% of predicted) 80.68 ±8.62 64.50 ±17.79 4.01 <0.001 
FVC 
(% of predicted) 87.68 ±7.98 73.10 ±14.96 4.19 <0.001 
PEFR 
(% of predicted) 78.10 ±14.8 59.50 ±26.96 2.92 <0.001 
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Table (5): Statistical comparison between asthmatics on ICS and asthmatics not on ICS) and control as 













GCR β(% of 




Table (6): Statistical correlation between  % of expression of GCR β and pulmonary function tests  in asthmatic 
patients 
GCR β 
   Variable R P 
FEV1 (% of predicted)    -0.00 >0.05 
PEFR (% of predicted)  - 0.42 <0.05 
 
FIG (1):Statistical comparison betw een control and asthmatics

































Fig. (2): Pearson correlation between GCRβ and PEFR  
in severe asthmatic cases 
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Fig. (3): Immuno-histochemical assay of % of expression of GCR β on PBMCs of male patient. He was diagnosed 
as severe persistent asthma not on inhaled steroids, his % of expression of GCR β on PBMCs was 17 % . 
 
 
Fig. (4): Immuno-histochemical assay of % of expression of GCR β on PBMCs of  male patient. He was diagnosed 




Discussion: GCR β is a hormone binding deficit isoform 
of GCR which has been isolated in humans   and when 
over expressed, it may function as a dominant negative 
modulator of GCR. 10 This study showed a statistically 
significant increase in percentage of expression of GCR 
β on PBMC's in asthmatic group (8.64±I4.35%) as 
compared to control group (2.05±0.99) (p<0.01).This 
was in agreement with Leung et al.,(1997) 16  and 
Hamid et al.,(1999) 13 who studied PBMC's from 15 
asthmatics and 8 controls by immuno-histochemistry for 
expression of GCR β,they found  significantly higher 
expression of GCR β in asthmatics compared to control, 
with higher level of expression in those less responsive 
to steroids. More recently GCRα and GCR β were 
studied in BAL cells of asthmatics and control .Lower 
level of GCRα and up regulation of  GCRβ in 
asthmatics with different grades of severity were 
detected.5,12 The exact mechanism for the increase in 
GCR β expression in peripheral blood cells of 
asthmatics is still under extensive studies but many 
investigators suggested that inflammatory milieu in 
asthmatic airways is contributing to expression of GCR 
β  and that increased expression of GCR β is cytokine 
inducible.3,7,19,25 
Bantel et al., (2000) 3 suggested that different cytokines 
may affect the rate of alternative splicing of 
glucocorticoid receptor or prolong half life of β isoform. 
Webster et al., (2001) 25 suggested that inflammatory 
cytokines may regulate GCR mRNA stability leading to 
a state where GCRα receptors are destabilized and 
GCRβ become more stable. Loke et al.200219 attributed 
the selective expression of GCRβ isoform in asthmatics 
to be both dose and time dependent on level of TNF-α 
with resulted increase in GCRβ specific mRNA. De 
Bosscher  et al, 2003 7 studied the antagonistic effect 
between glucocorticoids and NF-κB. They proved that 
this factor antagonize the transactivation function  of 
corticosteroids at the nuclear level by mediating 
changes in the level of GCRα and/or GCRβ with net 
result of increasing GCRβ. This provide new insights 
into the mechanism by which inflammation induces GC 
resistance and how defects in GCR may contribute to 
inflammation, creating the visious cycle leading to 
chronic inflammatory diseases .20 
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 On the contrary, Gagliardo et al, 2000 9 reported that, 
persistent release of other cytokines as IL-8 and GM-
CSF in glucocorticoid -dependent asthma is not 
associated with low expression of GCRα  or 
overexpression of GCRβ. 
This study showed a statistical significant higher 
percentage of expression of GCRβ isoform in severe 
asthmatics compared to both mild and moderate 
asthmatics and a statistical significant negative 
correlation between GCR β expression and PEFR. 
This is in agreement with Barnes (2006) 4 who stated 
that severe asthmatics are at risk of continuous exposure 
to allergens with release of different patterns of 
cytokines which reduce GCR binding affinity in 
mononuclear cells via increasing GCRβ .This was 
explained by increasing transcription factor activity in 
severe asthmatics which inhibit GCR/DNA interactions 
and may contribute to severity of the disease due to 
glucocorticoid insensitivity.5,17 Loke et al., (2002) 19) 
categorized a subset of asthmatics who do not respond 
to clinically relevant doses of GCs, and proved to have 
increased bronchial hyperreactivity, lower morning 
PEFR and a  longer duration of symptoms. Those 
patients had  alternative splicing isoform of GCR which 
is β isoform. More recently, PBMCs of patients with 
severe asthma were shown to express relative 
corticosteroid insensitivity due to over expression of 
GCR β. 14 Also it was observed increased expression of 
GCRβ on BAL macrophages at night in asthmatics with 
nocturnal worsening which was not observed in 
asthmatics without nocturnal exacerbations.6Their 
observations may contribute to nocturnal airway 
inflammation by inhibiting anti-inflammatory effects of 
glucocorticoids at night. 15 
In this study there was a  higher statistical significant 
increase in percentage of expression of  GCR β in 
asthmatic group not on inhaled steroid (11.70 ±3.62) 
comapred to asthmatics on inhaled steroids (6.20 ±3.20) 
(p<0.001).  
This is in agreement with Andersson et al., (1999)2 who 
studied in vivo modulation of GCR mRNA expression 
in 10 mild atopic asthmatics treated with fluticasone 
propionate (FP) 250 μg twice/day for 4 weeks. A 
significant reduction of GCR mRNA in endobronchial 
biopsy and more striking down regulation in peripheral 
blood were noticed after treatment due to control of 
inflammation and suppression of cytokines.  
On the other hand, Leung and Chrousos, (2000) 17 and 
Gagliardo et al.,(2001) 10 noticed that neutrophils in 
asthmatics on large doses of steroids, constitutively 
have higher level of expression of GCRβ. Thus failure 
of the patients to resolve their airway inflammation may 
be due to persistent neutrophilic inflammation with 
relatively higher level of  GCR β. 
Sousa et al.,(2000)22   and Miller and Chin(2006)20  
found that asthmatics who need higher doses and poorly 
responding to ICS showed a resistance of peripheral 
blood T-cells and monocytes to glucocorticoids in vitro 
and failure of ICS therapy to reduce expression of 
asthma relevant cytokines on airways in vivo. Those 
patients showed no abnormalities in glucocorticoid 
pharmacokinetics and are susceptible to development of 
cushingoid side effects of glucocorticoid therapy. This 
indicates that the defect in GC action in asthmatics is 
not generalized but it is attributed to T-cell and other 
inflammatory cells defects or abnormalities. 
The variation in steroid response in asthmatics can not 
be explained by pharmacokinetic mechanisms, by a 
defect in binding of steroids to its receptors, nor by 
defective nuclear translocation of this receptor. Chronic 
exposure to GC leads to down regulation of GCRα at 
both mRNA and protein level.1  Uncontrolled asthmatics 
on frequent interrupted courses of systemic steroids had 
reduced expression of GCRα relative to GCRβ which 
will render inflammatory cells subsequently insensitive 
to steroids. 22) On the contrary other studies do not 
support the hypothesis that increased GR-beta 
expression can contribute to cytokine-induced 
glucocorticoid insensitivity. 24  
Various data had been published about the percentage of 
expression of GCR β which could result in 
glucocorticoid insensitivity state. PBMCs with 
approximately 20% reactivity with GCRβ are associated 
with functional insensitivity to glucocorticoid.16 
However other investigators found that much lower 
level of GCRβ protein can achieve dominant negative 
regulative function. 25 
The clinical implication of higher expression of GCRβ 
has been related to the progressive increase in morbidity 
and mortality due to asthma in the past 3 decades. 
Increase number of GCRβ in airway cells of fatal 
asthma suggest that GCRβ may be a contributing factor 
to steroid insensitivity, leading to more deterioration in 
pulmonary functions and  asthma mortality. 12 This has 
been attributed to  increasing of airway inflammation 
which induces GCRβ expression with subsequent 
reduction in functional response to glucocorticoids. This 
proves the concept that inflammation dampens response 
to endogenous and exogenous glucocorticoid . 21 
The binding affinity of glucocorticoids to its receptor 
has clinical implication because ICS is the mainstay of 
treatment of severe asthma which is characterized by 
extensive inflammatory cytokines network. Some 
asthmatics are using higher doses of steroids for 
prolonged time, despite an initial response, any 
additional improvement may be impeded because the 
cells are now expressing predominant GCRβ which 
would not be anticipated to be steroid responsive. So it 
is important to recognize those patients as early as 
possible to avoid high dose therapy and serious adverse 
effects despite persistent airway compromise. 22   
In conclusion GCR beta may be important in the 
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pathogenesis of bronchial asthma which may be linked 
to asthma severity and can affect the response to ICS. 
So it is important to recognize those patients with high 
GCR beta to avoid high dose glucocorticoids serious 
adverse effects. 
Correspondence: 
Engy Yousry El Sayed 
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